CTXR_OUT_1 [2025-03-31 12:17:29 -0400] 2199 Bytes | 574 tokens | Cum: 574 tkns (7.17% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Citius Pharmaceuticals (CTXR) hit my radar screen, up to 2.05 from a prev close of 1.55 Do you think its got more juice or is it lacking potential? It's 12:17:27 PM on Mon Mar 31, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for Citius Pharmaceuticals:

C1 - Feb-14-25 04:30PM - Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
C2 - Feb-06-25 08:55AM - Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
C3 - Jan-08-25 08:00AM - Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
C4 - Jan-07-25 08:08AM - Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
C5 - Jan-07-25 08:08AM 07:57AM - Citius Oncology to explore strategic alternatives
C6 - Jan-06-25 07:50AM - Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
C7 - Dec-31-24 07:10AM - Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
C8 - Dec-30-24 09:43AM - American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Citius Pharmaceuticals (CTXR)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CTXR_OUT_3 [2025-03-31 12:17:32 -0400] 1101 Bytes | 305 tokens | Cum: 881 tkns (11.01% of 8k)
==========================================================================

Showing C4 (chunk 1 of 19): C4:
**Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025**
Date: Jan-07-25 08:08AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-and-citius-oncology-highlight-lymphir-commercial-launch-planned-for-the-first-half-of-2025-302344027.html

CRANFORD, N.J.,Jan. 7, 2025/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq:CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq:CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

"Sinc

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTXR_OUT_5 [2025-03-31 12:17:33 -0400] 585 Bytes | 158 tokens | Cum: 1107 tkns (13.84% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T16:24:06Z - Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com...
A2 - 2025-03-25T16:24:06Z - Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CTXR_OUT_7 [2025-03-31 12:17:37 -0400] 1098 Bytes | 295 tokens | Cum: 1404 tkns (17.55% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com**Date: 2025-03-25Source: {'uri': 'za.investing.com', 'dataType': 'news', 'title': 'Investing.com South Africa'}URL: https://za.investing.com/news/company-news/citius-pharmaceuticals-stock-hits-52week-low-at-145-93CH-3624436In a challenging turn of events for Citius Pharmaceuticals Inc (NASDAQ:CTXR), the company's stock has plummeted to $1.41, near its 52-week low of $1.47. According to InvestingPro analysis, the company's overall financial health score stands at 1.67, indicating a weak position. This significant downturn reflects a staggering 92.27% decline over the past year, with the stock falling 88% in just six months. Investors have watched with concern as the stock struggled to maintain its ground, ultimately succumbing to market pressures. While current metrics suggest the stock is undervalued, analysts

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTXR_OUT_9 [2025-03-31 12:17:38 -0400] 1044 Bytes | 308 tokens | Cum: 1714 tkns (21.43% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-07T13:08:00Z - Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
B2 - 2023-07-31T19:30:12Z - Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
B3 - 2023-07-31T12:31:01Z - Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
B4 - 2023-07-31T11:13:46Z - CSX, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
B5 - 2023-04-25T12:03:04Z - Why Aaron's Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
B6 - 2023-03-28T12:33:41Z - Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CTXR_OUT_11 [2025-03-31 12:17:43 -0400] 744 Bytes | 203 tokens | Cum: 1919 tkns (23.99% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/01/n42842249/citius-pharmaceuticals-and-citius-oncology-highlight-lymphir-commercial-launch-planned-for-the-firCitius Pharmaceuticals and its oncology subsidiary Citius Oncology announced preparations for the commercial launch of LYMPHIR, an immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, in the first half of 2025.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTXR_OUT_13 [2025-03-31 12:17:45 -0400] 1077 Bytes | 314 tokens | Cum: 2286 tkns (28.57% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-14 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

CITIUS PHARMACEUTICALS, INC.

COND CONS BAL SHEETS

(Unaudited)

December 31, September 30, 2024 2024 ASSETS Curr Assets: Cash and cash equiv $ 1,100,079 $ 3,251,880 Inventory 14,381,3...

S2 - 2025-01-08 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On January 7, 2025, Citius Pharmaceuticals, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) with certain institutional investors for the issuance and sale, in a registered direct off...

S3 - 2024-12-27 8-K Item 2.02 Results of Oper and Fin Cond.

On December 27, 2024, we issued a press release announcing our results of operations for the full year of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CTXR_OUT_15 [2025-03-31 12:17:52 -0400] 1098 Bytes | 379 tokens | Cum: 2667 tkns (33.34% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31, September 30, 2024 2024 ASSETS Current Assets: Cash and cash equivalents $ 1,100,079 $ 3,251,880 Inventory 14,381,369 8,268,766 Prepaid expenses 2,845,739 2,700,000 Total Current Assets 18,327,187 14,220,646 Operating lease right-of-use asset, net 191,412 246,247 Deposits 38,062 38,062 In-process research and development 92,800,000 92,800,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 102,184,858 Total Assets $ 120,703,457 $ 116,651,751 LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Accounts payable $ 7,364,120 $ 4,927,211 License payable 28,400,000 28,400,000 Accrued expenses 6,242,178 17,027 Accrued compensation 2,595,091 2,229,018 Operating lease liability 204,569 241,547 Total Current Liabili

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTXR_OUT_17 [2025-03-31 12:18:09 -0400] 4190 Bytes | 1200 tokens | Cum: 4015 tkns (50.19% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+----------------------+
| Volume: 1,388,800 | Perf Month: 18.18% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 151.69K | Perf Quarter: -41.09% | Short Float: 6.39% | ROE: -52.85% |
+---------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 21.79 | Index: - | Short Ratio: 3.41 | ROI: -62.26% |
+---------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 57.16 | Market Cap: 16.76M | Short Interest: 0.52M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.23 | Shs Outstand: 8.59M | Beta: 1.17 | EPS Surprise: 4.76% |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA20: 22.87% | Shs Float: 8.10M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA50: -8.78% | Inst Own: 8.33% | Sales past 5Y: 0.00% | Earnings: Feb 14 AMC |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA200: -78.81% | Insider Own: 5.74% | Employees: 23 | |
+---------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 25.81% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -39425839.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.17
Average Volume: 226217.48
30-Day High: 2.17
30-Day Low: 1.3

[Detailed Financials: TTM 2024]
- Total Assets: $116,651,751.0
- Total Liabilities: $42,549,921.0
- Total Equity: $74,101,830.0
- Current Assets: $14,220,646.0
- Current Liabilities: $35,814,803.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.97

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-23,229,048.0

[Detailed Financials: FY 2024]
- Total Assets: $116,651,751.0
- Total Liabilities: $42,549,921.0
- Total Equity: $74,101,830.0
- Current Assets: $14,220,646.0
- Current Liabilities: $35,814,803.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.97

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-23,229,048.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CTXR_OUT_19 [2025-03-31 12:18:15 -0400] 676 Bytes | 167 tokens | Cum: 4483 tkns (56.04% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CTXR_IN_21 [2025-03-31 12:18:15 -0400] 126 Bytes | 29 tokens | Cum: 4600 tkns (57.50% of 8k)
==========================================================================

====================================
[2025-03-31 12:18:15] # Analysis Completed
Elapsed Time: 48.00 seconds